Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-09-03

Clinical Trial Update: A Placebo Controlled, Randomized, Double Blind Trial of Milnacipran for the Treatment of Idiopathic Neuropathy Pain [Phase 3]

View source ↗

Summary

Phase 3 randomized, placebo-controlled trial of milnacipran for idiopathic peripheral neuropathy pain; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Milnacipran (milnacipran)

Snippet

Sponsor: Columbia University | Conditions: Idiopathic Peripheral Neuropathy | Phase 3 | Status: TERMINATED | Results posted: 2020-09-03